Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
NCT05588609Phase 2Terminated
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zenocutuzumab in non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC). Started Nov 2022; status: terminated.
02
Drugs
zenocutuzumab
03
Conditions
non-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05588609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588609.